Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TCR-T-CMV
- Development stage
- Unknown
- Lead developer
- Immunotech Biopharm
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
TCR-T-CMV is an investigational gene-modified T cell receptor (TCR-T) therapy being developed by Immunotech Biopharm (Yongtai Biology) for the treatment of cytomegalovirus (CMV) infection in patients following hematopoietic stem cell transplantation (HSCT). The therapy consists of autologous T cells that are genetically engineered to express specific TCRs designed to recognize and eliminate CMV-infected cells. By targeting CMV antigens presented on the surface of infected cells, TCR-T-CMV aims to restore cellular immunity against the virus in immunocompromised post-transplant patients, thereby preventing or treating potentially life-threatening CMV complications. The product is currently in Phase 1 clinical development in China.
- Other names
- TCR-T-CMV injection
02
Targets
pp65/HLA-A*02:01 (CMV pp65 peptide-HLA-A*02:01 complex)
Beyond the preview
Go deeper on TCR-T-CMV.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TCR-T-CMV.